Nivolumab following CAR-T failure in multiple myeloma and non-Hodgkin lymphoma: results of a phase 2 study

Abstract: We conducted a single-center open-label phase 2 trial of the programmed cell death protein 1 (PD-1) inhibitor nivolumab for patients with multiple myeloma (MM) or non-Hodgkin lymphoma (NHL) following failure of last-line chimeric antigen receptor T-cell (CAR-T) therapy. The primary end poi...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	Rahul Banerjee, Sylvain Simon, Jenna M. Voutsinas, Qian Vicky Wu, Daria Gausman, Joshua Dizon, Ethan Xie, Cecilia C. S. Yeung, Minggang Lin, Ryan C. Lynch, Chaitra S. Ujjani, Brian G. Till, Mary L. Kwok, Sarah S. Lee, Rebecca Silbermann, Eva Medvedova, Peter Wilcox, Jorge Ramos, Mazyar Shadman, Jordan Gauthier, Cameron J. Turtle, Damian J. Green, Ajay K. Gopal, Stanley R. Riddell, Andrew J. Cowan
Format:	Artigo
Sprog:	Inglês
Udgivet:	Elsevier 2026-03-01
Serier:	Blood Immunology & Cellular Therapy
Online adgang:	http://www.sciencedirect.com/science/article/pii/S3050597625000223
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!